Creative Planning Sarepta Therapeutics, Inc. Transaction History

Creative Planning

  • $101 Billion
  • Q3 2024

A detailed history of Creative Planning transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Creative Planning holds 7,677 shares of SRPT stock, worth $873,028. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,677
Previous 7,937 3.28%
Holding current value
$873,028
Previous $1.25 Million 23.6%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024
SELL
$124.33 - $156.75 $32,325 - $40,755
-260 Reduced 3.28%
7,677 $958,000
Q2 2024

Aug 15, 2024
BUY
$113.33 - $163.85 $93,950 - $135,831
829 Added 11.66%
7,937 $1.25 Million
Q1 2024

May 10, 2024
BUY
$93.7 - $141.53 $103,444 - $156,249
1,104 Added 18.39%
7,108 $920,000
Q4 2023

Feb 14, 2024
SELL
$67.31 - $124.76 $1.15 Million - $2.14 Million
-17,159 Reduced 74.08%
6,004 $578,000
Q3 2023

Nov 16, 2023
BUY
$102.5 - $123.59 $68,162 - $82,187
665 Added 2.96%
23,163 $2.81 Million
Q2 2023

Jul 21, 2023
BUY
$106.4 - $157.19 $17,236 - $25,464
162 Added 0.73%
22,498 $2.58 Million
Q1 2023

May 15, 2023
BUY
$117.53 - $155.99 $46,424 - $61,616
395 Added 1.8%
22,336 $3.08 Million
Q4 2022

Feb 10, 2023
BUY
$100.86 - $132.13 $30,056 - $39,374
298 Added 1.38%
21,941 $2.84 Million
Q3 2022

Nov 03, 2022
SELL
$75.71 - $119.24 $35,735 - $56,281
-472 Reduced 2.13%
21,643 $2.39 Million
Q2 2022

Aug 15, 2022
SELL
$62.69 - $88.44 $62 - $88
-1 Reduced -0.0%
22,115 $1.66 Million
Q1 2022

May 16, 2022
SELL
$63.15 - $90.42 $315 - $452
-5 Reduced 0.02%
22,116 $1.73 Million
Q4 2021

Feb 11, 2022
SELL
$77.28 - $99.42 $96,831 - $124,573
-1,253 Reduced 5.36%
22,121 $1.99 Million
Q3 2021

Nov 10, 2021
SELL
$65.97 - $92.48 $236,700 - $331,818
-3,588 Reduced 13.31%
23,374 $2.16 Million
Q2 2021

Aug 04, 2021
SELL
$69.38 - $86.75 $389,568 - $487,101
-5,615 Reduced 17.24%
26,962 $2.1 Million
Q1 2021

Apr 30, 2021
SELL
$72.25 - $168.95 $202,733 - $474,073
-2,806 Reduced 7.93%
32,577 $2.43 Million
Q4 2020

Jan 29, 2021
BUY
$125.56 - $178.74 $94,546 - $134,591
753 Added 2.17%
35,383 $6.03 Million
Q3 2020

Nov 05, 2020
BUY
$127.12 - $172.34 $867,339 - $1.18 Million
6,823 Added 24.54%
34,630 $4.86 Million
Q2 2020

Jul 23, 2020
BUY
$93.0 - $171.7 $39,060 - $72,114
420 Added 1.53%
27,807 $4.46 Million
Q1 2020

May 05, 2020
SELL
$82.38 - $131.64 $2.68 Million - $4.28 Million
-32,501 Reduced 54.27%
27,387 $2.68 Million
Q4 2019

Jan 30, 2020
BUY
$76.53 - $135.58 $578,796 - $1.03 Million
7,563 Added 14.45%
59,888 $7.73 Million
Q3 2019

Nov 01, 2019
SELL
$72.81 - $156.91 $4.18 Million - $9.02 Million
-57,465 Reduced 52.34%
52,325 $3.94 Million
Q2 2019

Jul 26, 2019
SELL
$112.21 - $151.95 $2.23 Million - $3.02 Million
-19,900 Reduced 15.34%
109,790 $16.7 Million
Q1 2019

Apr 24, 2019
BUY
$106.67 - $151.68 $6.35 Million - $9.02 Million
59,487 Added 84.74%
129,690 $15.5 Million
Q4 2018

Feb 01, 2019
SELL
$97.32 - $148.76 $897,679 - $1.37 Million
-9,224 Reduced 11.61%
70,203 $7.66 Million
Q3 2018

Oct 25, 2018
BUY
$115.31 - $161.51 $954,766 - $1.34 Million
8,280 Added 11.64%
79,427 $12.8 Million
Q2 2018

Jul 20, 2018
SELL
$71.74 - $153.69 $1.13 Million - $2.41 Million
-15,703 Reduced 18.08%
71,147 $9.4 Million
Q1 2018

Apr 18, 2018
SELL
$54.02 - $82.27 $639,218 - $973,500
-11,833 Reduced 11.99%
86,850 $6.44 Million
Q4 2017

Jan 17, 2018
SELL
$47.64 - $56.75 $241,677 - $287,892
-5,073 Reduced 4.89%
98,683 $5.49 Million
Q3 2017

Oct 17, 2017
BUY
$35.73 - $47.15 $3.71 Million - $4.89 Million
103,756
103,756 $4.71 Million

Others Institutions Holding SRPT

# of Institutions
525
Shares Held
84.4M
Call Options Held
2.06M
Put Options Held
1.52M
View Full List

About Sarepta Therapeutics, Inc.

SRPT Quotes by TradingView
  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $9.96B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email